Evidence map›Paper›PMID 39982530›Full record

ArticleCurrent microbiology2025

Determining the Antimycobacterial Action of Rottlerin Against Mycobacterium Species and Toxicity, Antioxidant Properties, and Therapeutic Target Affinity of Rottlerin.

Jaqueline Lopes Damasceno, Mariana Brentini Santiago, Ralciane de Paula Menezes, Tábata Rodrigues Esperandim, Saulo Duarte Ozelin, Marília Vitória Franco da Silva, Uriel Rodrigues Landaeta, Denise Crispim Tavares, Luis Carlos Scalon Cunha, Eloísa Amália Vieira Ferro and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jaqueline Lopes DamascenoLaboratory of Antimicrobial Testing, Institute of Biomedical Sciences, Federal University of Uberlândia, Uberlândia, Minas Gerais, Brazil.
Mariana Brentini SantiagoLaboratory of Antimicrobial Testing, Institute of Biomedical Sciences, Federal University of Uberlândia, Uberlândia, Minas Gerais, Brazil.
Ralciane de Paula MenezesTechnical School of Health, Federal University of Uberlândia, Uberlândia, Minas Gerais, Brazil.
Tábata Rodrigues EsperandimLaboratory of Mutagenesis, University of Franca, Franca, São Paulo, Brazil.
Saulo Duarte OzelinLaboratory of Mutagenesis, University of Franca, Franca, São Paulo, Brazil.
Marília Vitória Franco da SilvaLaboratory of Mutagenesis, University of Franca, Franca, São Paulo, Brazil.
Uriel Rodrigues LandaetaLaboratory of Mutagenesis, University of Franca, Franca, São Paulo, Brazil.
Denise Crispim TavaresLaboratory of Mutagenesis, University of Franca, Franca, São Paulo, Brazil.
Luis Carlos Scalon CunhaChemistry Department, Federal Institute of Triângulo Mineiro, Uberaba, Minas Gerais, Brazil.
Eloísa Amália Vieira FerroLaboratory of Immunophysiology of Reproduction, Institute of Biomedical Sciences, Federal University of Uberlândia, Uberlândia, Minas Gerais, Brazil.
Thales Alves de Melo FernandesLaboratory of Applied Toxinology, Butantan Institute, Av. Vital Brasil 1500, Butantã, São Paulo, SP, CEP 05503-900, Brazil.
Carlos Henrique Gomes MartinsLaboratory of Antimicrobial Testing, Institute of Biomedical Sciences, Federal University of Uberlândia, Uberlândia, Minas Gerais, Brazil. carlos.martins2@ufu.br.ORCID http://orcid.org/0000-0001-8634-6878

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 150679/2021-1Fundação de Amparo à Pesquisa do Estado de Minas Gerais APQ-02067-22
6 · The paper itself

Abstract

Infections by Mycobacterium spp. are responsible for thousands of deaths every year worldwide. Microbial resistance, toxic effects, and adverse consequences of conventional therapies bring forth the need to search for new therapeutic agents. The aim of this study was to determine the antimicrobial action of the molecule Rottlerin against Mycobacterium spp. The broth microdilution assay showed that Rottlerin inhibited the mycobacterial growth at concentrations ≤ 50 µg/mL (≤ 96.81 µM), and the lowest bactericidal concentration was observed against M. tuberculosis (25 µg/mL-48.40 µM). The cytotoxicity of Rottlerin was conducted in a epithelial cell culture and evaluated through 2,3-Bis-(2-Methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) colorimetric assay, revealing an IC

Indexed as

AcetophenonesAnti-Bacterial AgentsAntioxidantsAntitubercular AgentsBenzopyransMycobacteriumHumansMicrobial Sensitivity TestsMolecular Docking SimulationMycobacterium tuberculosisAcetophenonesAnti-Bacterial AgentsAntioxidantsAntitubercular AgentsBenzopyransrottlerin

Identifiers

PMID39982530

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.